<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>Annals of Internal Medicine: HIV Topic Collection</title>
    <link>http://annals.org/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Tue, 07 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Mon, 06 May 2013 22:53:57 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@annals.org</managingEditor>
    <webMaster>webmaster@annals.org</webMaster>
    <item>
      <title>HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease A Cohort Study </title>
      <link>http://annals.org/article.aspx?articleID=1655859</link>
      <pubDate>Tue, 07 May 2013 00:00:00 GMT</pubDate>
      <author>Kirk GD, Mehta SH, Astemborski J, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;&lt;/div&gt;Chinese translation&lt;div class="boxTitle"&gt;Background:&lt;/div&gt;Persons with HIV infection have been reported to develop age-related diseases at younger ages than those without HIV. Whether this finding is related to HIV infection or failure to control for other risk factors is unknown.&lt;div class="boxTitle"&gt;Objective:&lt;/div&gt;To investigate whether persons with HIV infection develop hepatitis C virus (HCV)–related liver disease at younger ages than similar persons without HIV.&lt;div class="boxTitle"&gt;Design:&lt;/div&gt;Comparison of the severity of liver fibrosis by age among persons who have HCV with and without HIV followed concurrently in the same protocol.&lt;div class="boxTitle"&gt;Setting:&lt;/div&gt;Observational cohort from Baltimore, Maryland, participating in the ALIVE (AIDS Linked to the IntraVenous Experience) study.&lt;div class="boxTitle"&gt;Participants:&lt;/div&gt;1176 current and former injection drug users with antibodies to HCV.&lt;div class="boxTitle"&gt;Measurements:&lt;/div&gt;Liver fibrosis assessed semiannually from 2006 to 2011 by elastography (FibroScan, Echosens, Paris, France) and using previously validated thresholds for clinically significant fibrosis and cirrhosis; concurrent assessment of medical history, alcohol and illicit drug use, HCV RNA levels, hepatitis B virus surface antigen level, body mass index, and (for those with HIV) CD4&lt;sup&gt;+&lt;/sup&gt; lymphocyte count and HIV RNA levels.&lt;div class="boxTitle"&gt;Results:&lt;/div&gt;Among 1176 participants with antibodies to HCV, the median age was 49 years and 34% were coinfected with HIV and HCV. Participants contributed 5634 valid liver fibrosis measurements. The prevalence of clinically significant fibrosis without cirrhosis (12.9% vs. 9.5%) and of cirrhosis (19.5% vs. 11.0%) was greater in persons coinfected with HIV and HCV than in those with only HCV (&lt;span style="font-style:italic;"&gt;P&lt;/span&gt; &lt; 0.001). Increasing age and HIV infection were independently associated with liver fibrosis, as were daily alcohol use, chronic hepatitis B virus infection, body mass index greater than 25 kg/m&lt;sup&gt;2&lt;/sup&gt;, and greater plasma HCV RNA levels. When these factors were kept constant, persons with HIV had liver fibrosis measurements equal to those of persons without HIV, who were, on average, 9.2 years older.&lt;div class="boxTitle"&gt;Limitation:&lt;/div&gt;The process of liver fibrosis began before the study in most persons.&lt;div class="boxTitle"&gt;Conclusion:&lt;/div&gt;In this cohort, persons who have HCV with HIV have liver fibrosis stages similar to those without HIV who are nearly a decade older.&lt;div class="boxTitle"&gt;Primary Funding Source:&lt;/div&gt;National Institute on Drug Abuse.&lt;/span&gt;</description>
      <guid>http://annals.org/article.aspx?articleID=1655859</guid>
    </item>
  </channel>
</rss>